Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial

Mösges, R.; Bachert, Claus; Panzner, Petr; Calderón, Moisés A.; Haazen, L.; Pirotton, Sabine; Wathelet, Nathalie; Durham, Stephen R.; Bonny, Marie-Alix; Legon, Thierry; Frenckell, R. von; Pfaar, Oliver; Shamji, Mohamed H.

doi:10.1111/all.13433

Cited by 45 publications

(38 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, allergen‐specific immunotherapy (AIT) is the only curative treatment that induces clinical and immunological tolerance to causative allergens in allergic patients . AIT efficiently decreases symptoms of allergic asthma, rhinitis, and insect sting allergy . A primary feature of AIT is to change the course of the disease by changing the underlying pathology on local and systemic immune response .…”

Section: Introductionmentioning

confidence: 99%

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Boonpiyathad

Sokołowska

Morita

et al. 2019

Allergy

View full text Add to dashboard Cite

Background: Allergen-specific immunotherapy (AIT) is the only available treatment for allergic diseases that can induce specific immune tolerance to allergens. The key mechanisms involved in this process include changes in allergen-specific regulatory T (Treg) cells. Methods:We studied 25 allergic rhinitis patients undergoing subcutaneous house dust mite-specific immunotherapy. Peripheral blood mononuclear cells were studied before and after 10, 30 weeks, and 3 years of AIT. Der p 1-specific T regulatory cell responses were investigated by characterization of Der p 1-MHC class II tetramerpositive cells and correlated with nasal symptom score. Results: Twelve of 25 AIT patients matched with their MHC class II expression to the Der p 1 peptide-MHC class II tetramers. A significant increase in the numbers of Der p 1-specific FOXP3 + Helios + CD25 + CD127 − Treg cells after 30 weeks was observed, which slightly decreased after 3 years of AIT. In contrast, Der p 1-specific immunoglobulin-like transcript 3 (ILT3) + CD25 + Treg cells decreased substantially from baseline after 3 years of AIT. ILT3 + Treg cells displayed compromised suppressive function and low FOXP3 expression. In addition, Der p 1-specific IL-10 and IL-22 responses have increased after 30 weeks, but only IL-10 + Der p 1-specific Treg cells remained present at high frequency after 3 years of AIT. Increased number of FOXP3 + Helios + and IL-10 + and decreased ILT3 + Treg cell responses correlated with improved allergic symptoms. Conclusion: The results indicate that AIT involves upregulation of the activated allergen-specific Treg cells and downregulation of dysfunctional allergen-specific Treg cell subset. Correction of dysregulated Treg cells responses during AIT is associated with improved clinical response. K E Y W O R D Sallergen-specific T cells, antigen-specific immunotherapy, house dust mite allergy, Treg Abbreviations: AIT, antigen-specific immunotherapy; AR, allergic rhinitis; HDM, house dust mite; ILT3, immunoglobulin-like transcript 3; Treg, T regulatory.

show abstract

Section: Introductionmentioning

confidence: 99%

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Boonpiyathad

Sokołowska

Morita

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…Recent studies confirmed AIT with grass allergen peptides (170 μg over 3 weeks) 110,111 and depigmented polymerized allergen extracts 112 as safe and effective treatments for local AR caused by grass pollen sensitization. A maximum cumulative dose of 490 μg of the grass pollen peptides was well tolerated with only a few minor adverse reactions.…”

Section: Allerg En Immunother Apy ( Ait )mentioning

confidence: 89%

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

show abstract

“…Allergen hydrolysates broaden the number of potential T cell epitopes to optimize T cell and B cell responses while maintaining hypoallergenicity. A phase IIb SCIT study assessed the efficacy and the safety of short‐course AIT with peptide hydrolysates from Lolium perenne (LPP) pollen allergens . The treatment induced a modest reduction in the combined symptom and medication score (18% along the entire pollen season).…”

Section: T Cell Epitope Peptidesmentioning

confidence: 99%

Molecular approaches to allergen‐specific immunotherapy: Are we so far from clinical implementation?

Pechsrichuang

Jacquet

2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Conventional allergen-specific immunotherapy (AIT), based on administrations of allergen extracts, represents up to now the unique protocol for the desensitization of allergic patients. Whereas the effectiveness of AIT was evidenced for the treatment of allergic rhinitis and allergic asthma, such strategy remains experimental for food allergies up to now. However, important issues are commonly associated with AIT as the quality of natural allergen extracts, the long duration and adverse side-effects which negatively affect successful desensitization together with the patient compliance. The rapid progression of molecular allergology made possible the quest of safer, shorter and more effective immunotherapeutic approaches. The aim of this review was to provide an update on these different innovative recombinant derivatives including their efficacy but also their limitations. Despite promising preclinical and early clinical studies, the absence of convincing data in large phase III trials precludes so far the translation of these immunotherapeutic candidates into the clinic. K E Y W O R D S allergen-specific immunotherapy, blocking antibodies, clinical trial, efficacy, hypoallergenic, recombinant derivatives, safety, Treg Present AIT Delivery route SCIT SLIT Molecules Allergen extracts +/-Adjuvant Alum 26Abbreviations: 8x6Q2W, grass allergen peptides at 6 nmol at 2-wk intervals for a total of 8

show abstract

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial

Cited by 45 publications

References 29 publications

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Highlights and recent developments in airway diseases in EAACI journals (2018)

Molecular approaches to allergen‐specific immunotherapy: Are we so far from clinical implementation?

Contact Info

Product

Resources

About